BD Announces CE Marking Of A New Molecular Test To Diagnose Patients With Clostridium Difficile Infections
Jul 8th 2008Drug InformationGastroIntestinal / Gastroentorology
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced the CE marking of the BD GeneOhm(TM) Cdiff molecular assay for the rapid diagnosis of patients with Clostridium difficile infection (CDI). It is the first CDI diagnostic test that offers sensitivity, simplicity and speed in one test procedure. BD has also submitted this assay to the U.S. Food and Drug Administration for clearance.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
